It was sort of an odd day in the market. It actually felt worse than it was earlier in the day, partly because we started with some strength and then.
It was an odd day in the market with weakness early followed but a rally in the afternoon that made it look like we would get to unchanged (or even.
[This was meant to be posted Friday afternoon but did not seem to go through, so you get a bonus EOD of today] I do not think there is not.
Rough day in the market today and biotechs were clearly not immune. Aside from the general downtrend there were some stock specific stories. 1. There was some strategic restructuring at.
Happy mid-ASCO (although most of the data is already presented). Some interesting ASCO and, surprisingly, non-ASCO stories. 1. I added to my SGEN position today (at $33.67). It has been.
A bit of a quite day today in the markets. There is some biotech news but it seems to be the calm before the storm of ASCO, or as I.
This is mid-day instead of the end of the day because I will be out of the office for the rest of the afternoon. This is a little shorter than.
Really another slow day entering into the long weekend. From my perspective, there were really only two really interesting moves. 1. AVEO was a bit of a shocker. AVEO disclosed.
Today was another macro day in that the macro environment had a lot more to do with price movements than fundamentals. That being said, bios seemed to be strong in.
While the market got some intraday whipsaw action, it seemed generally good and biotechs did well- early. We had a late day sell-off with biotechs seeming to do better than.
Perhaps it is the start of the summer season but the market seems to have been quite the past couple of days or perhaps I am simply looking at the.
Outside of a not completely unexpected merger, it was a relatively quite start to the week. As has been par for the course, ASCO oncology stocks tended to be weak.
It seemed to be a quite day as I think everyone is recovering from the ASCO abstract dump. 1. I had some good discussion with people about the PGNX abstract.